Patents by Inventor John T. Isaacs
John T. Isaacs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911027Abstract: A surgical stapler, or fastening instrument, may generally comprise a layer, such as a tissue thickness compensator, for example, releasably attached to a fastener cartridge and/or anvil by a flowable attachment portion. The flowable attachment portion may be indefinitely flowable. The flowable attachment portion may be flowable from the time that layer is installed to the fastener cartridge to the time in which the layer is implanted to patient tissue. The flowable attachment portion may comprise a pressure sensitive adhesive. The flowable attachment portion may comprise an adhesive laminate comprising a base layer comprising the tissue thickness compensator and an adhesive layer on at least a portion of a surface of the base layer comprising the pressure sensitive adhesive. Articles of manufacture comprising flowable attachment portion and methods of making and using the flowable attachment portion are also described.Type: GrantFiled: November 15, 2019Date of Patent: February 27, 2024Assignee: Cilag GmbH InternationalInventors: Taylor W. Aronhalt, Michael J. Vendely, Lauren S. Weaner, Brandon J. Lloyd, Frederick E. Shelton, IV, Michael J. Miller, Michael T. Isaacs, Emily Ann Schellin, John V. Hunt, John E. Feds
-
Publication number: 20230331694Abstract: The present disclosure relates to FAP-activated prodrugs that can be used in the treatment of cancer, such as prostate cancer. The disclosure also relates to pharmaceutical compositions comprising the prodrugs, and related methods of treatment.Type: ApplicationFiled: July 29, 2021Publication date: October 19, 2023Inventors: W. Nathaniel Brennen, John T. Isaacs, Samuel R. Denmeade, Emmanuel S. Akinboye
-
Publication number: 20210205408Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.Type: ApplicationFiled: March 16, 2021Publication date: July 8, 2021Inventors: John T. Isaacs, Samuel R. Denmeade, W. Nathaniel Brennen
-
Patent number: 10967046Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.Type: GrantFiled: March 11, 2020Date of Patent: April 6, 2021Assignee: The Johns Hopkins UniversityInventors: John T. Isaacs, Samuel R. Denmeade, W. Nathaniel Brennen
-
Publication number: 20200268836Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.Type: ApplicationFiled: March 11, 2020Publication date: August 27, 2020Inventors: John T. Isaacs, Samuel R. Denmeade, W. Nathaniel Brennen
-
Patent number: 10596226Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.Type: GrantFiled: January 15, 2016Date of Patent: March 24, 2020Assignee: The Johns Hopkins UniversityInventors: John T. Isaacs, Samuel R. Denmeade, W. Nathaniel Brennen
-
Publication number: 20180148480Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for using synthetically enhanced T-cells to treat cancer. The present invention also provides a T-cell engineered (a) to express at least one CAR that binds tumor antigens; and (b) to inducibly express a prostate-specific antigen (PSA)-activated pro-aerolysin (PA) upon tumor antigen recognition by CAR.Type: ApplicationFiled: January 15, 2016Publication date: May 31, 2018Inventors: John T. Isaacs, Samuel R. Denmeade, Nathaniel E. Brennen
-
Publication number: 20180008668Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.Type: ApplicationFiled: January 15, 2016Publication date: January 11, 2018Inventors: John T. Isaacs, Samuel R. Denmeade, Nathaniel E. Brennen
-
Patent number: 8957016Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.Type: GrantFiled: May 31, 2012Date of Patent: February 17, 2015Inventors: Samuel R. Denmeade, John T. Isaacs
-
Patent number: 8822406Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.Type: GrantFiled: May 31, 2012Date of Patent: September 2, 2014Assignee: GenSpera, Inc.Inventors: Samuel R. Denmeade, John T. Isaacs
-
Patent number: 8450280Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.Type: GrantFiled: May 16, 2012Date of Patent: May 28, 2013Assignee: GenbSpera, Inc.Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
-
Publication number: 20120309692Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.Type: ApplicationFiled: May 16, 2012Publication date: December 6, 2012Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
-
Publication number: 20120270767Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.Type: ApplicationFiled: May 31, 2012Publication date: October 25, 2012Inventors: Samuel R. Denmeade, John T. Isaacs
-
Publication number: 20120270768Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the thug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.Type: ApplicationFiled: May 31, 2012Publication date: October 25, 2012Inventors: Samuel R. Denmeade, John T. Isaacs
-
Publication number: 20110245147Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.Type: ApplicationFiled: January 10, 2011Publication date: October 6, 2011Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
-
Patent number: 7906477Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.Type: GrantFiled: November 18, 2003Date of Patent: March 15, 2011Assignee: Genspera, Inc.Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
-
Patent number: 7838266Abstract: Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed.Type: GrantFiled: May 27, 2010Date of Patent: November 23, 2010Assignees: University of Victoria Innovation and Development Corporation, The Johns Hopkins UniversityInventors: Samuel R. Denmeade, John T. Isaacs, J. Thomas Buckley
-
Publication number: 20100234300Abstract: Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed.Type: ApplicationFiled: May 27, 2010Publication date: September 16, 2010Inventors: Samuel R. Denmeade, John T. Isaacs, J. Thomas Buckley
-
Patent number: 7745395Abstract: Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed.Type: GrantFiled: September 17, 2007Date of Patent: June 29, 2010Assignees: University of Victoria Innovatiion and Development Corporation, The Johns Hopkins UniversityInventors: Samuel R. Denmeade, John T. Isaacs, J. Thomas Buckley
-
Publication number: 20100120697Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.Type: ApplicationFiled: November 5, 2009Publication date: May 13, 2010Inventors: Samuel R. Denmeade, John T. Isaacs